Form 4: Coya Therapeutics Director Acquires Stock Options
SEC Form 4
Dov A. Goldstein, a director of Coya Therapeutics, acquired stock options for 5,000 shares on February 25, 2025.
Summary
- On February 25, 2025, Dov A. Goldstein, a director of Coya Therapeutics, acquired stock options for 5,000 shares.
- The exercise price of the stock options is $5.97.
- The options vest 100% on the first anniversary of the grant date, subject to continuous service.
- The options expire on February 25, 2035.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. The acquisition itself can be viewed as mildly positive, but the filing is routine.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the trading activities of company insiders, such as directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Date of transaction: Dov A. Goldstein acquired stock options. |
| 02/25/2025 | Date of signature. |
| 02/25/2026 | Vesting date: 100% of the options will vest on this date, subject to continuous service. |
| 02/25/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.